Fortis Healthcare Ltd. posted a strong performance in the second quarter of fiscal year 2026, with key financials showing material improvement year-on-year. The company’s consolidated revenue rose 17.3% to ₹2,331 crore in Q2 FY26 from ₹1,988 crore in the same period last year. Operating EBITDA increased 27-28% to ₹556 crore (from around ₹435 crore a year ago), delivering an EBITDA margin of approximately 23.9%, up from ~21.9% in Q2 FY25. Profit after tax (PAT) surged by 82.4% to ₹322 crore in Q2 FY26 versus ₹176 crore a year ago.
In discussion of the half‐year ending September 30, 2025 (H1 FY26), Fortis reported consolidated revenue of ₹4,498 crore , up approximately 16.9% year-on-year, and a PAT of ₹582 crore, up about 70.1% from ₹342 crore in H1 FY25. Commenting on the results, Dr Ashutosh Raghuvanshi, MD & CEO of Fortis Healthcare, noted that the company “has maintained a healthy growth momentum across both our hospital and diagnostics businesses. In the hospital segment, key specialties such as Oncology and Renal Sciences grew by 29% and 22% respectively compared to the same period last year.”
Regional Performance
The company reports its segment-wise revenue: for Q2, the “Healthcare” segment (hospitals) generated INR 19,738.2 m (≈ ₹1,973.82 crore) and the “Diagnostics” segment generated INR 3,996.3 m (≈ ₹399.63 crore). Management commentary indicates stronger focus and expansion in core regions such as the NCR (National Capital Region), Mumbai, Bengaluru, and Punjab.
Operational updates include the company entering into a lease agreement for a 200-bed multi-specialty hospital in Greater Noida (which the company had earlier operated under an O&M arrangement) and a new operations & management (O&M) arrangement for a 550-bed super specialty hospital in Lucknow to be constructed by the Ekana Group. These moves expand Fortis’ presence in Delhi NCR to approximately 2,100 beds.
To summarise Fortis Healthcare delivered robust volume and margin growth in Q2 FY26, with all major metrics — revenue, EBITDA, PAT — showing double-digit gains. Its specialty segments are showing strong momentum and the company is actively expanding its bed base and operations. The challenge going ahead will be sustaining the margin improvement, managing the expansion capex and scaling operations profitably.
